Introduction {#sec1}
============

Hereditary angioedema (HAE) is a hereditary disease presenting with recurrent angioedema attacks. This swelling with unclear margins not accompanied by pain develops as a result of plasma postcapillary venules leaking in dermal layers of the dermis. This leakage basically derives from a lack of or insufficient activity of a protein called C1 esterase inhibitor \[[@cit0001], [@cit0002]\].

The disease is relatively rare. Reported frequencies range from 1 : 10,000 to 1 : 150,000 with 1 : 50,000 as the best overall estimate. This would indicate that there are roughly 500--7,000 people with HAE in Turkey \[[@cit0003]--[@cit0006]\].

This disease has hereditary properties and is considered autosomal dominant \[[@cit0007]\]. This means that it does not omit a generation and arise in each generation. No ethnic or sexual differences are known. C1 esterase inhibitor levels are about 50% in a heterozygote individual at birth, and symptoms do not generally start before C1 esterase inhibitor levels decrease below 35%. Reduced C1 esterase inhibitor levels and the subsequent clinical presentation of HAE typically occurs within the first two decades \[[@cit0008]\]. The disease tends to deteriorate by puberty and then last for the remainder of individuals' lifetime.

The frequency and severity of attacks may vary greatly across patients and even in the same patient in different years \[[@cit0009]\]. The symptoms usually tend to be more severe in patients with early onset than in patients with late onset \[[@cit0010]\]. Some patients may experience mild attacks that recover without requiring any therapy, while others frequently have severe attacks that require emergency care. Moreover, the course of an attack cannot be estimated on the basis of prior baseline symptoms. Thus, the diagnosis of patients with discountable mild attacks, as early as possible, may prevent these patients from dying as a result of a laryngeal oedema attack.

Angioedema attacks are not often life-threatening, although they tend to be disruptive. An exception to this is the occurrence of swelling in the respiratory tract. More than 50% of cases of HAE experience at least one laryngeal oedema episode. Laryngeal symptoms generally appear at later ages and are rare before the age of 3 \[[@cit0011]\]. If the attack begins in the mouth and affects the respiratory tract, a clinical presentation blinding the glottis and leading to mortality with asphyxia may develop. The mortality rate may increase up to 50% in cases of undiagnosed HAE \[[@cit0012]\]. Although it has such a high mortality risk, HAE is diagnosed on average 8.5 years after the first symptoms appear \[[@cit0013]\]. It is essential to screen the relatives of index HAE patients for the disease.

C4 levels are low both during and between attacks for nearly all HAE cases. Thus, C4 is a very appropriate screening test in diagnosis. Subsequently, the determination of C1 esterase inhibitor levels and functioning helps both to diagnose and differentiate between type I (C1 esterase inhibitor level is low, C1 esterase inhibitor function is decreased) and type II HAE (C1 esterase inhibitor level is normal, C1 esterase inhibitor function is decreased) \[[@cit0014]\].

With HAE, one's mortality rate can rise up to 50% when the condition is left undiagnosed; thus, an early diagnosis and the use of medicines can save patients' lives.

Aim {#sec2}
===

We therefore aimed to screen all relatives of our patients who live in two different villages for HAE by looking at our type I HAE index case. We also investigated for mutations of the C1 esterase inhibitor gene.

Material and methods {#sec3}
====================

Subjects {#sec3.1}
--------

In our study, HAE screening was performed in two villages on a total of 124 individuals (in the first village -- 70, in the other village -- 54) as a result of the investigation conducted on relatives of the index case with a diagnosis of type I HAE. A family pedigree was constructed with 124 related individuals distributed in 3 generations. All individuals, with ages ranging from 1 to 82 years old, were interviewed and had blood samples collected and analysed for C4 and C1 esterase inhibitor levels. Physical examinations were performed. All 124 subjects were evaluated for HAE, including measurements of C4 and C1 esterase inhibitor and the diagnosis was established according to consensus criteria \[[@cit0011], [@cit0014]\]. C1 esterase inhibitor activity was investigated in patients with low C4 levels. We investigated for mutations of the C1 esterase inhibitor gene in 5 patients with HAE and 1 patient without HAE. Genomic DNA was extracted from peripheral blood. Complete sequencing of the coding region of the SERPING1 gene was carried out.

HAE severity score {#sec3.2}
------------------

A simplified HAE severity score was constructed based on the score proposed by the Third C1 Esterase Inhibitor Deficiency Workshop \[[@cit0015]\]. Episodes of angioedema were classified according to the average frequency and intensity of symptoms since the onset of the disease. The frequency of symptoms was quantitated as follows: more than 1 episode a month, 3 points; between 6 and 11 episodes a year, 2 points; \< 6 episodes a year, 1 point; and no symptoms of angioedema, 0 points. The intensity of symptoms was classified as follows: the presence of discomfort but no disruption in daily activity, 2 points; discomfort reducing normal daily activity, 4 points; and an inability to work or perform daily activity and/or the need for hospital care, 5 points. The sum of the frequency and intensity scores was used to classify the severity of the disease as follows: severe (≥ 7 points); moderate (5 or 6 points); mild (≤ 4 points); and asymptomatic (0 points).

Measurement of C1 esterase inhibitor, C1 esterase inhibitor activity and C4 levels {#sec3.3}
----------------------------------------------------------------------------------

Serum C4 levels were determined by Siemens C4 Complement reagent, BN Prospec Nephelometry, with normal values ranging from 15 to 45 mg/dl. Serum C1 esterase inhibitor levels were determined by Siemens C1 esterase inhibitor reagent, BN Prospec Nephelometry, with normal values ranging from 0.15 to 0.35 g/l.

Serum C1 esterase inhibitor activity levels were studied using TechnochromeC1 esterase inhibitor activity reagent, chromogenic (photometric) detection with Amax 200 analyser (C1 inhibitor functional levels ≤ 40% of normal are considered decreased).

Identification of DNA mutations {#sec3.4}
-------------------------------

Selected by the geneticist, the gene assay was performed in 3 patients with type I HAE, 2 patients with type II, and 1 healthy person. Genomic DNA was extracted from peripheral blood. SERPING1 gene mutation analysis was performed by sequencing the coding exons and exon-intron boundaries of the gene in the Ege University, Department of Medical Genetics. Genomic DNA was extracted from peripheral EDTA anticoagulant whole blood using the MagNAPure LC automated system (Roche Applied Science, Manheim, Germany) following the manufacturer's instructions. To amplify the coding exons of the SERPING1 gene, primers were used, as listed in [Table 1](#t0001){ref-type="table"}. The PCR fragments were sequenced by the Illumina MiSeq system using V2 chemistry (Illumina, Ca, USA). The sequencing results were analysed using IGV software (<http://www.broadinstitute.org/igv/>).

###### 

Primers used to amplify the coding exons of the SERPING1 gene

  ------------- -----------------------
  C1-INH 1-2F   TACAGGAACTCACACCAGCG
  C1-INH 1-2R   TTAATCCTCAGCCACCGCCC
  C1-INH 3F     TTTAGAGGACTGTGCCTCG
  C1-INH 3R     GGCTTTGTAAGTGTCTGG
  C1-INH 4F     CTCCAAAGCAGGGAATACC
  C1-INH 4R     GGTCTTCACCTGCTCTGCAG
  C1-INH 5-6F   CTCCACCATGCCGTATTCA
  C1-INH 5-6R   GGCTAGAGAAAGGAGAAGGAG
  C1-INH 7F     CAGACTGCAGGACAGCATTG
  C1-INH 7R     AACTTGCAGGGTTGCAGGAC
  C1-INH 8F     CTGGGACTCAGGATGAACCC
  C1-INH 8R     CAAGTCCAGGCAGGCAGCAG
  ------------- -----------------------

Ethics approval {#sec3.5}
---------------

All study procedures were done in accordance with a protocol previously approved by the Ethics Committee of the Gaziantep University. All parents provided written informed consent to the study procedures, and the children also gave consent.

Statistical analysis {#sec3.6}
--------------------

A statistical software package was used for all data analyses and comparisons (SPSS v 11.5). The data were tested for assumptions of normalcy, and differences between the groups were compared with the Mann-Whitney *U*-test and x^2^ test. A *p*-value of less than 0.05 was considered significant.

Results {#sec4}
=======

The demographic characteristics of all screened individuals are shown in [Table 2](#t0002){ref-type="table"} and clinic and laboratory characteristics are shown in [Table 3](#t0003){ref-type="table"}. The number of screened males was 60 (48.4%) and females was 64 (51.6%). Features of patients with HAE presented in [Table 4](#t0004){ref-type="table"}.

###### 

Demographic characteristics of all screened individuals

  Parameter                                                                   Patients with HAE (*n* = 42)   Healthy (*n* = 82)   *P*-value
  --------------------------------------------------------------------------- ------------------------------ -------------------- ----------------------------------------------
  Age[\*](#tf2-1){ref-type="table-fn"}                                        16.95 ±14.82                   23.0 ±19.01          0.14[^\#^](#tf2-2){ref-type="table-fn"}
  Gender (M/F)                                                                24/18                          36/46                0.165[\*\*](#tf2-3){ref-type="table-fn"}
  C4 level \[mg/dl\][\*](#tf2-1){ref-type="table-fn"}                         7.08 ±2.64                     24.76 ±8.15          \< 0.0001[^\#^](#tf2-2){ref-type="table-fn"}
  C1 esterase inhibitor level \[g/l\][\*](#tf2-1){ref-type="table-fn"}        0.09 ±0.06                     0.27 ±0.05           \< 0.001[^\#^](#tf2-2){ref-type="table-fn"}
  C1 esterase inhibitor activity level (%)[\*](#tf2-1){ref-type="table-fn"}   2.76 ±7.56                     --                   --
  HAE Severity Score[\*](#tf2-1){ref-type="table-fn"}                         2.02 ±3.22                     --                   --
  Age \> 18 HAE Severity Score[\*](#tf2-1){ref-type="table-fn"}               5.36 ±3.52                     --                   --
  Age ≤ 18 HAE Severity Score[\*](#tf2-1){ref-type="table-fn"}                0.84 ±2.11                     --                   --
  Age of the onset of the first symptoms[\*](#tf2-1){ref-type="table-fn"}     12.38 ±10.49                   --                   --
  Age of diagnosis[\*](#tf2-1){ref-type="table-fn"}                           16.95 ±14.82                   --                   --

Mean ± SD

Mann-Whitney U test

x^2^ test.

###### 

Clinic and laboratory characteristics of healthy individuals and patients

  Parameter                                                                              Patients with HAE (*n* = 42)                    Healthy (*n* = 82)   *P*-value[^\#^](#tf3-1){ref-type="table-fn"}
  -------------------------------------------------------------------------------------- ----------------------------------------------- -------------------- ----------------------------------------------
  Male/female                                                                            24/18 (57/43%)20/15 type I HAE4/3 type II HAE   36/46 (43.9/56.1%)   
  Symptoms of painful swelling in the body                                               13 (30.9%)                                      23 (28%)             0.737
  Symptoms of painful swelling on the face                                               13 (30.9%)                                      23 (28%)             0.737
  Symptoms of painful swelling due to trauma                                             13 (30.9%)                                      23 (28%)             0.737
  Symptoms of painful swelling after tooth extraction                                    9 (21.4%)                                       6 (7.3%)             0.023
  Symptoms of painful swelling after exercise, sorrow or alcohol intake                  13 (0.9(%3)                                     20 (24.4%)           0.436
  Symptoms of hoarseness, feeling of obstruction in the throat and shortness of breath   13 (30.9%)                                      18 (22)              0.275
  Symptoms of severe abdominal pain                                                      13 (30.9%)                                      19 (23.2%)           0.351
  Symptoms of severe abdominal pain accompanied by vomiting and diarrhoea                13 (30.9%)                                      19 (23.2%)           0.351
  Symptoms of patients had undergone abdominal operations at any time in their lives     0 (0%)                                          0 (0%)               1.000
  Patients who were hospitalized in intensive care due to laryngeal oedema               1 (2.3%)                                        1 (1.2%)             0.628
  Patients with low C4 level                                                             42 (100%)                                       0 (0%)               \< 0.001
  Patients with low C1 esterase inhibitor level                                          35 (83%)                                        0 (0%)               \< 0.001
  Patients with low C1 esterase inhibitor activity level                                 42 (100%)                                       --                   --

Mann-Whitney U test.

###### 

Features of patients with HAE

  No.   Age \[years\]   Gender (M/F)   Age at onset of symptoms \[year\]   Age of diagnosis \[year\]   Severity score   C4 \[mg/dl\]   C1 esterase inhibitor \[g/l\]   C1 esterase inhibitor activity (%)   HAE type I/II
  ----- --------------- -------------- ----------------------------------- --------------------------- ---------------- -------------- ------------------------------- ------------------------------------ ---------------
  1     2               F              --                                  2                           0                7.39           0.11                            2.9                                  I
  2     27              F              10                                  27                          8                5.6            0.06                            0.03                                 I
  3     48              F              15                                  48                          8                5.6            0.08                            0                                    I
  4     16              M              --                                  16                          0                5.6            0.03                            0.25                                 I
  5     14              F              --                                  14                          0                5.6            0.06                            0.14                                 I
  6     11              F              --                                  11                          0                5.8            0.08                            0                                    I
  7     8               M              --                                  8                           0                5.6            0.06                            0.37                                 I
  8     6               F              --                                  6                           0                5.6            0.09                            0.9                                  I
  9     4               F              --                                  4                           0                5.6            0.08                            1                                    I
  10    10              M              --                                  10                          0                5.63           0.07                            0                                    I
  11    16              F              --                                  16                          0                5.6            0.04                            0                                    I
  12    12              M              --                                  12                          0                5.6            0.05                            0                                    I
  13    6               M              --                                  6                           0                5.6            0.04                            0                                    I
  14    17              M              5                                   17                          8                5.6            0.04                            1.2                                  I
  15    45              M              15                                  45                          6                5.6            0.08                            0.14                                 I
  16    9               F              2                                   9                           5                5.6            0.09                            0.2                                  I
  17    2               M              --                                  2                           0                6.33           0.14                            0.09                                 I
  18    15              M              --                                  15                          0                5.6            0.08                            0.25                                 I
  19    7               F              --                                  7                           0                7.58           0.12                            0                                    I
  20    17              M              --                                  17                          0                5.6            0.08                            0.03                                 I
  21    41              F              15                                  41                          8                5.6            0.07                            0                                    I
  22    16              M              5                                   16                          7                5.6            0.04                            0.14                                 I
  23    18              M              --                                  18                          0                5.6            0.03                            0                                    I
  24    10              M              --                                  10                          0                5.6            0.04                            1.07                                 I
  25    8               M              --                                  8                           0                9.95           0.08                            0.14                                 I
  26    26              F              15                                  26                          8                5.6            0.05                            0                                    I
  27    6               M              --                                  6                           0                5.6            0.09                            0                                    I
  28    2               M              --                                  2                           0                6.71           0.11                            2.19                                 I
  29    39              M              --                                  39                          0                5.6            0.06                            0                                    I
  30    10              F              --                                  10                          0                12.8           0.26                            38                                   II
  31    8               M              --                                  8                           0                11.3           0.2                             9.7                                  II
  32    6               M              --                                  6                           0                5.6            0.07                            1.24                                 I
  33    1               M              --                                  1                           0                5.6            0.16                            6.1                                  II
  34    32              M              16                                  32                          7                5.6            0.05                            0                                    I
  35    1               F              1                                   1                           3                5.83           0.08                            0.71                                 I
  36    58              F              20                                  58                          8                12.2           0.07                            0                                    I
  37    4               F              2                                   4                           3                5.6            0.07                            0                                    I
  38    31              M              --                                  31                          0                9.07           0.11                            0.48                                 I
  39    52              F              40                                  52                          6                13.5           0.2                             0.31                                 II
  40    23              F              --                                  23                          0                14.1           0.24                            24.2                                 II
  41    15              M              --                                  15                          0                11.4           0.21                            21.9                                 II
  42    13              M              --                                  13                          0                12.1           0.22                            2.25                                 II

Results of C4, C1 esterase inhibitor and C1 esterase inhibitor activity levels {#sec4.1}
------------------------------------------------------------------------------

C4 levels were low in 42 of the 124 screened individuals; 35 of these 42 individuals were diagnosed with type I HAE due to their low C1 esterase inhibitor levels and activity. C1 esterase inhibitor activity was also low in all patients with low C4 levels. Thus, 7 patients were diagnosed with type II HAE due to their low C4, low C1 esterase inhibitor activity and normal C1 esterase inhibitor levels. Forty-two individuals, or 30% of the screened individuals who were not diagnosed with HAE previously, were diagnosed with HAE by means of our screening, and patients were recommended appropriate therapies (C1 esterase inhibitor concentrate during HAE attack periods) after they were informed about the disease and given HAE patient cards.

The age at first symptom onset (mean: 12.38 ±10.49) ranged between 1 and 40 years, while the age at diagnosis (mean: 16.95 ±14.82) ranged between 1 and 58 years. Thirty-one patients (73.8%) diagnosed with HAE were 18 or younger; 11 of them (26.2%) were older than 18. Twenty-six of the 31 patients who were 18 and younger were diagnosed with type I HAE; 5 of them were diagnosed with type II HAE. Twenty-six of the 31 patients who were 18 and younger had no symptoms; 5 of them were symptomatic, and all of these patients with symptoms had a type I HAE diagnosis. We had 2 patients at the age of 1 and younger, and one of them was diagnosed with type I HAE and symptomatic at the same time; the other patient was diagnosed with type II HAE and asymptomatic. There were no age differences between diseased (16.95 ±14.82) and healthy (23.00 ±19.01) groups (*p* = 0.14).

The C4 and C1 esterase inhibitor levels of patients who were diagnosed with HAE were significantly lower than the healthy group ((7.08 ±2.64 mg/dl vs. 24.76 ±8.15 mg/dl, *p* \< 0.0001) and (0.09 ±0.06 g/l vs. 0.27 ±0.05 g/l, *p* \< 0.001), respectively). A positive correlation was found between C1 esterase inhibitor and C4 levels in the entire group (*p* \< 0.0001, *r* = 0.801, *n* = 124) ([Figure 1](#f0001){ref-type="fig"}). The mean C1 esterase inhibitor activity level of the diseased group was 2.76 ±7.56. A positive correlation was found between the C1 esterase inhibitor activity levels and C4 levels of patients with HAE (*p* \< 0.0001, *r* = 0.631, *n* = 42).

![**A** -- Correlation between C4 levels and C1 esterase inhibitor levels of cases. **B** -- Correlation between C4 levels and C1 esterase inhibitor activity levels](PDIA-36-78898-g001){#f0001}

Relationship between HAE severity scores and the age of patients with an HAE diagnosis {#sec4.2}
--------------------------------------------------------------------------------------

Twelve of 35 patients (34.3%) with type I HAE were symptomatic, while 1 of 7 patients (14.3%) with type II HAE was symptomatic. The HAE severity scores of patients with symptomatic type I HAE ranged between 2 and 5 (mean: 4.0 ±1.3, 4.5, IQR: 2.5--5), while the score of one symptomatic type II HAE patient was 4.

The severity scores of HAE patients who were 18 and younger (mean: 0.84 ±2.11) were lower than those of patients older than 18 (mean: 5.36 ±3.52) (*p* \< 0.0001). A positive correlation was found between the age at diagnosis and the severity score of patients with HAE (*p* \< 0.0001, *r* = 0.651, *n* = 42), while no correlation was found between the age at diagnosis and C4, C1 esterase inhibitor, and C1 esterase inhibitor activity levels. A positive correlation was found between the age of first symptom onset of symptomatic HAE patients and the age at diagnosis (*p* = 0.006, *r* = 0.714, *n* = 13), C4 levels (*p* = 0.001, *r* = 0.824, *n* = 13), and C1 esterase inhibitor activity levels (*p* = 0.002, *r* = 0.774, *n* = 13); however, no correlation was found for C1 esterase inhibitor activity levels.

Relationship between HAE severity scores and C1 esterase inhibitor activity levels {#sec4.3}
----------------------------------------------------------------------------------

The C1 esterase inhibitor activity levels of HAE patients with severity scores of 4 to 8 were significantly lower than those with severity scores of 0 to 3 ((0.01 (IQR 0.0--0.18) vs. 0.25 (0.0--1.9); *p* = 0.077)) ([Figure 2](#f0002){ref-type="fig"}). While marginally significant, a negative correlation was found between C1 esterase inhibitor activity levels and severity scores in the HAE group older than 18 (*p* = 0.1, *r* = --0.515, *n* = 11); no correlation was found between C1 esterase inhibitor levels and severity scores (*p* = 0.14, *r* = --0.476, *n* = 11).

![Relationship between HAE severity scores and C1 esterase inhibitor activity levels](PDIA-36-78898-g002){#f0002}

Mutation analysis of the SERPING1 gene {#sec4.4}
--------------------------------------

We analysed three type I HAE patients, including our index case, and two type II HAE patients and one healthy person without HAE, for the mutation in the SERPING1 gene ([Figure 3 A](#f0003){ref-type="fig"}). In the light of the clinical findings, the *SERPING1* coding region (ENST00000278407) was analysed in our index case (III-3) and subjects II-15 and III-11, and a novel heterozygous 1033G\>T missense variant was identified in these patients with type I HAE, substituting tryptophan for the evolutionarily conserved glycine, located in the serpin protease inhibitor domain of the protein (p.Gly345Trp) ([Figures 3 B, C](#f0003){ref-type="fig"}). This variation is not reported in the dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP/>), the 1000 genome database ([www.1000genomes.org](http://www.1000genomes.org)) and the human gene mutation database (<http://www.hgmd.cf.ac.uk/ac/index.php>). This mutation site is conserved among vertebrates and mutation prediction *in silico* programs, SIFT (<http://sift.jcvi.org>) and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) predict that this mutation is significantly a disease causing one. In addition, to analyse the effect of this substitution on the protein structure, wild-type and the predicted p.Gly345Trp-SERPING1 protein sequences were evaluated using SWISS-MODEL (<http://swissmodel.expasy.org>) ([Figure 3 D](#f0003){ref-type="fig"}). The Z-score of the estimated model was --2.03 (PMID: 9504803, 16301204, 12824332). While all 3 patients with type I HAE were positive for the 1033G\>T mutation, one healthy person without HAE, shown as II-12 in pedigree, had no defect in the SERPING1 gene. Finally, we could not detect any defect in the *SERPING1* gene in 2 patients, represented as II-17 and IV-39 in pedigree, with type II HAE.

![**A** -- The HAE family pedigree. Note that the black boxes indicate type I HAE; however, subjects II.17, III.23, III.24, III.25, IV.38, IV.39 and IV.40 have type II HAE, interestingly, in the same family. **B** -- Display of the Integrative Genomics Viewer (IGV) showing the *SERPING1* novel heterozygous c.1033G\>T missense variant. The grey letter represents the wildtype nucleotides and the red letter represents a single base-nucleotide alteration. **C** -- The *SERPING1* gene structure and the location of the functional domain (serpin protease inhibitor) are indicated. The conservation of 345^th^ glycine residue among species. Conserved glycine is shown with the arrow (Information Conservation). **D** -- The wild-type protein and defective protein, respectively, covering the regions of serpin protease inhibitor, as presented in the SWISS-MODEL work space window](PDIA-36-78898-g003){#f0003}

The family pedigree is shown in [Figure 3 A](#f0003){ref-type="fig"}.

Discussion {#sec5}
==========

In the present study, 124 patients from two villages were screened by looking at the index case in our study. Of them, 42 patients were diagnosed with HAE; 35 patients had type I HAE and 7 type II HAE, and 74% of these 42 patients were 18 or younger. Approximately one out of every 3 patients was diagnosed with HAE. A positive correlation was detected between C4 levels and C1 esterase inhibitor levels and C1 esterase inhibitor activity levels and between the age at diagnosis and severity scores. A negative correlation was detected between C1 esterase inhibitor activity levels and severity scores. The C1 esterase inhibitor activity of patients with high HAE clinical severity was lower than those with low HAE clinical severity. We also reported an additional missense heterozygous c.1033G\>T mutation (p.G345T) of the SERPING1 gene in patients with type I HAE.

Out of patients who could be diagnosed by means of our screening, 26 of 35 type I HAE patients and 5 of 7 type II HAE patients were 18 years old or younger. We consider that the quality of life and survival times of paediatric patients who have a long forthcoming lifetime would increase with early diagnosis.

Furthermore, 29% of the 124 screened patients had an experience of body swelling, facial swelling and swelling as a result of trauma, and this was seen in 31% of patients in which HAE was detected. These results indicate that these questions are not helpful in this screening period.

Of the 124 patients screened, 12% experienced swelling due to tooth extraction. A total of 21% of the diseased group had swelling due to tooth extraction. The question about swelling following tooth extraction was observed to be a distinguishing question in HAE diagnosis.

In addition, 31% of the diseased group experienced swelling at any time in their life after exercise or sorrow, 31% had a severe stomach ache at any time in their life, and in 31%, the stomach ache was accompanied by vomiting and diarrhoea. None of the patients experienced abdominal surgery. These ratios are also similar to the ratio of 25% mentioned by Kasamatsu *et al.* \[[@cit0016]\]. A severe stomach ache was reported by Lei *et al.* in 18.2% \[[@cit0017]\].

Moreover, 31% of the diseased group experienced hoarseness or an obstruction in their throat at any time in their life. Lei *et al.* \[[@cit0017]\] also found laryngeal oedema in 45.5%. Three members of the family we screened had died due to laryngeal oedema and asphyxia; 2.35% of the diseased group received inpatient treatment in an intensive care unit at any time of their life.

A total of 60% of screened individuals were 18 or younger. HAE was detected in 42% of 74 individuals in this age group. HAE was detected in 22% of 50 individuals who were older than 18. None of the cases were previously diagnosed, except the index case. It should be noted that none of the patients who were diagnosed during our screening were previously diagnosed. This situation indicates the importance of screenings performed by looking at the index case. Patients do not suspect themselves to have the disease, although they have the same symptoms as their relatives who were diagnosed with HAE, and they try to keep the diagnosis away from them. Only 31% of all patients were symptomatic, compared to 57.9% of patients in the reports of Lei *et al.* \[[@cit0017]\]. As most of the patients we diagnosed were younger than 18, symptoms were considered as potentially not developed yet. Skin findings, laryngeal oedema findings and abdominal findings existed in the reports of all symptomatic patients. Skin findings were present in all symptomatic patients in a report by Lei *et al.* \[[@cit0017]\]. One unique family had 4 members who were diagnosed with type I or type II HAE in the same family. In this family, 3 siblings were diagnosed with type II, while 1 sibling was diagnosed with type I HAE.

Delay in diagnosis would likely have been much longer in some patients without screening. This delay was found to be 8.45 years in the study conducted by Lei *et al.* \[[@cit0017]\]. The average age at diagnosis was 16.95, with a diagnosis delay of 4.57 years in our study with the aid of our screening.

As well as having low C1 esterase inhibitor levels from birth, symptoms appear when C1 esterase inhibitor levels fall below 35% by the nature of the disease as the patient grows up and HAE symptom scores are increased. In support of this, in the HAE patients that we diagnosed, symptoms appeared as the patients grow up, and there was a negative correlation between symptom scores and C1 esterase inhibitor activity in patients older than 18 years. Furthermore, it was demonstrated that the C1 esterase inhibitor activity of patients with high HAE clinical severity was lower than those with low HAE clinical severity. Similarly, a relationship was discovered between C1 esterase inhibitor activity levels and HAE severity in a study conducted by Ferraro *et al.* \[[@cit0018]\]. In our study, we could detect marginally significant relationships between C1 esterase inhibitor activity and HAE symptom scores due to the fact that we had a few patients older than 18 and most of the patients under 18 were asymptomatic.

In our study, we found that symptom scores were high in HAE patients with lower diagnosis age. These results are in accordance with those reported in the literature \[[@cit0010]\]. In addition, we showed in our study that screening tests may provide better results than surveys as patients are often asymptomatic at early ages. Thus, screening tests should be performed on the relatives of the patients with HAE and early diagnosis should be achieved. Ferraro *et al.* emphasized that the initial symptoms may not appear until after 40 years of age; therefore, particularly during younger ages, a lack of symptoms does not exclude the possibility of the disease \[[@cit0018]\]. Hence, our patients who were older than 18 were detected to have higher HAE symptom scores than those who were under 18.

Another important finding we detected during our screening was the existence of a very strong correlation between C4 levels and C1 esterase inhibitor levels and activity. This result once more revealed that the use of a simple C4 test was an accurate and strong tool to be used for HAE screening.

Finally, as another important finding of our study, here we report an additional missense heterozygous c.1033G\>T mutation (p.G345T) of the *SERPING1* gene in patients with type I HAE. The missense variant found in the evolutionarily ultra-conserved serpin protease inhibitor domain of the C1-Inhibitor (C1Inh) gene and cause hereditary angioedema.

Conclusions {#sec6}
===========

There are long periods of delay in the diagnosis of HAE and when the index case is present, family screening may be very important, and even life-saving. In particular, in paediatric patients without symptoms, screening tests are more important as surveys are inadequate in diagnosing. Furthermore, the present study provides evidence to link a novel mutation, c.1033G\>T, to the development of HAE in a large HAE family from Turkey.
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